ALLR
Allarity Therapeutics, Inc. NASDAQ Listed Dec 21, 2021$1.01
+4.65%
vs $0.97
Mkt Cap $16.1M
52w Low $0.77
22.5% of range
52w High $1.84
50d MA $1.27
200d MA $1.24
P/E (TTM)
—
EV/EBITDA
—
P/B
1.5x
Debt/Equity
0.1x
ROE
-114.3%
P/FCF
-0.9x
RSI (14)
25.20
ATR (14)
$0.11
Beta
0.01
50d MA
$1.27
200d MA
$1.24
Avg Volume
112.3K
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
210 Broadway · Boston, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | AMC | -0.25 | -0.21 | +16.0% | 1.37 | +1.5% | -2.2% | +0.7% | +5.9% | +0.0% | -0.7% | — |
| May 15, 2026 | AMC | -0.22 | -0.17 | +22.7% | 1.35 | +2.2% | +5.9% | +4.2% | +0.0% | +11.4% | +6.6% | — |
| Mar 31, 2026 | AMC | -0.22 | -0.19 | +13.6% | 1.09 | +1.8% | +3.7% | +2.7% | +1.7% | -1.7% | +0.0% | — |
| Nov 14, 2025 | AMC | -0.23 | -0.19 | +17.4% | 1.18 | +0.0% | -5.1% | +1.8% | -6.1% | -7.2% | +6.8% | — |
| Aug 15, 2025 | AMC | -0.21 | -0.15 | +28.6% | 0.96 | -2.9% | -5.0% | -0.5% | -4.0% | +1.2% | +7.5% | — |
| May 9, 2025 | AMC | — | -0.25 | — | 1.05 | -3.8% | -2.9% | +2.0% | -6.7% | +4.1% | +3.0% | — |
| Apr 4, 2025 | AMC | -8.10 | -4.73 | +41.6% | 0.79 | -9.0% | +0.6% | -5.6% | -6.6% | +3.3% | +0.8% | — |
| Nov 14, 2024 | AMC | -8.52 | -7.71 | +9.5% | 1.41 | -0.7% | -6.4% | -8.3% | +3.3% | -4.8% | +5.9% | — |
| Aug 5, 2024 | AMC | -0.29 | -3.30 | -1037.9% | 4.64 | +0.0% | -5.8% | -4.1% | +1.4% | +4.5% | -0.5% | — |
| May 14, 2024 | AMC | -1.76 | -664.86 | -9999.0% | 23.66 | -7.1% | -13.8% | -1.1% | -5.0% | -1.8% | -7.7% | — |
| Apr 29, 2024 | AMC | — | -175.51 | — | 41.40 | -2.2% | -8.0% | +7.9% | -10.2% | -18.7% | -9.9% | — |
| Mar 8, 2024 | AMC | -0.25 | -0.43 | -72.0% | 240.54 | +4.3% | +0.1% | -3.2% | -6.4% | -3.8% | -0.9% | — |
| Nov 14, 2023 | AMC | -8.17 | -1345.35 | -9999.0% | 288.00 | +3.0% | +3.1% | -0.9% | +6.0% | -3.9% | +2.0% | — |
| Aug 14, 2023 | AMC | -11.19 | -15783.78 | -9999.0% | 1260.00 | -2.4% | -7.6% | -6.7% | -5.0% | -5.8% | +8.0% | — |
| May 11, 2023 | AMC | -7.88 | — | -9999.0% | 10200.00 | -5.9% | -10.0% | +0.1% | -7.7% | -2.4% | -8.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.15 | $1.18 | +2.6% | +10.4% | -6.3% | +0.0% | +5.0% | -0.8% |
| Dec 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.16 | $1.16 | +0.0% | -1.7% | +2.6% | -1.7% | -0.9% | -7.0% |
| Sep 26 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.54 | $1.52 | -1.3% | +2.6% | +0.6% | -0.6% | +2.5% | +0.0% |
| Aug 23 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| May 27 | Ladenburg Thalmann | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 29
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 16
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 14
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 1
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics released a material press announcement, though the specific details requiring investor attention are referenced in the attached exhibit but not disclosed in this filing summary.
Jun 22
8-K · 5.02
!!! Very High
Allarity Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 2
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics disclosed a material announcement via press release but the 8-K filing does not specify the announcement's content, leaving investors without concrete details on the reported event.
May 6
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics announced a material event requiring disclosure, with details provided in the press release filed as an exhibit to this 8-K report.
Apr 28
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics filed a material press release via 8-K but the specific announcement details are referenced in the exhibit rather than disclosed in the summary provided.
Apr 22
8-K
Unknown — 8-K Filing
Allarity's FDA Fast Track designation for stenoparib accelerates potential approval timelines and validates clinical efficacy, reducing development risk and increasing probability of market success for this dual-mechanism cancer drug.
Apr 1
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics issued a press release announcement, though the specific details require reviewing the attached exhibit to determine the material event's impact on shareholders.
Mar 9
8-K · 1.01
! Medium
Allarity Therapeutics, Inc. -- 8-K 1.01: Financing / Debt Agreement
Allarity Therapeutics secured financing from Streeterville Capital, LLC, providing the cash resources needed to support ongoing operations and clinical development programs.
Mar 6
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics filed a material announcement via press release, though the specific details require reviewing the attached exhibit to understand the company event's impact on shareholders.
Feb 19
8-K · 8.01
!! High
Allarity Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Allarity Therapeutics issued a material announcement via press release; investors should review Exhibit 99.1 for specific details about the company development or corporate event disclosed.
Feb 4
Institutional (13F) — Top 10
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Renaissance Technologies Llc | 331,509 | $428K | Added | Jun 2026 |
| 2 | Citadel Advisors Llc | 183,496 | $237K | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 171,795 | $222K | — | Jun 2026 |
| 4 | Militia Capital Management Llc | 98,978 | $128K | New | Jun 2026 |
| 5 | Northern Trust Corp | 48,103 | $52K | Added | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 27,492 | $35K | — | Jun 2026 |
| 7 | Ubs Group Ag | 23,158 | $25K | Reduced | Mar 2026 |
| 8 | Caitong International Asset Management Co., Ltd | 22 | $28 | New | Jun 2026 |
| 9 | Virtu Financial Llc | 15,322 | $20 | New | Jun 2026 |
| 10 | Danske Bank A/s | 1 | $1 | — | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 86,159 | $84K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 22,166 | $36K | May 2026 |
| 3 | Fidelity Series Total Market Index Fund | 21,595 | $35K | May 2026 |
Valuation
Market Cap
$16.1M
Enterprise Value
-$810K
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
1.48x
P/S
42.09x
P/FCF
-0.94x
EV/EBITDA
—
Shares Out
14.4M
Financials (TTM)
Revenue
$345K
Net Income
-$12.3M
EBITDA
-$11.1M
Free Cash Flow
-$14.8M
Op Cash Flow
-$14.8M
EPS Basic
$-0.78
EPS Diluted
$-0.78
EPS Forward
$-0.96
Gross Margin
107.5%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$18.3M
Total Liab.
$8.4M
Total Equity
$9.8M
Cash
$14.7M
LT Debt
$0
Book Value/Sh
$0.68
Debt/Equity
0.14x
Current Ratio
2.13
Quick Ratio
2.13
Returns & Growth
ROE
-114.3%
ROA
-61.5%
ROIC
-112.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+95.1%
Price Returns
2W
-13.1%
1M
-31.6%
3M
-25.2%
6M
-7.2%
12M
-38.9%
Technicals
52W High
$1.84
52W Low
$0.77
50d MA
$1.27
200d MA
$1.24
RSI (14)
25.20
ATR (14)
$0.11
Beta
0.01
Avg Volume
112K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 5:22pm
· Source: financialmodelingprep.com